241 related articles for article (PubMed ID: 19053780)
1. Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
Berardi F; Abate C; Ferorelli S; de Robertis AF; Leopoldo M; Colabufo NA; Niso M; Perrone R
J Med Chem; 2008 Dec; 51(23):7523-31. PubMed ID: 19053780
[TBL] [Abstract][Full Text] [Related]
2. Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
Laggner C; Schieferer C; Fiechtner B; Poles G; Hoffmann RD; Glossmann H; Langer T; Moebius FF
J Med Chem; 2005 Jul; 48(15):4754-64. PubMed ID: 16033255
[TBL] [Abstract][Full Text] [Related]
3. Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase.
Paul R; Silve S; De Nys N; Dupuy PH; Bouteiller CL; Rosenfeld J; Ferrara P; Le Fur G; Casellas P; Loison G
J Pharmacol Exp Ther; 1998 Jun; 285(3):1296-302. PubMed ID: 9618436
[TBL] [Abstract][Full Text] [Related]
4. Yeast sterol C8-C7 isomerase: identification and characterization of a high-affinity binding site for enzyme inhibitors.
Moebius FF; Bermoser K; Reiter RJ; Hanner M; Glossmann H
Biochemistry; 1996 Dec; 35(51):16871-8. PubMed ID: 8988026
[TBL] [Abstract][Full Text] [Related]
5. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
[TBL] [Abstract][Full Text] [Related]
6. Cloning of an emopamil-binding protein (EBP)-like protein that lacks sterol delta8-delta7 isomerase activity.
Moebius FF; Fitzky BU; Wietzorrek G; Haidekker A; Eder A; Glossmann H
Biochem J; 2003 Aug; 374(Pt 1):229-37. PubMed ID: 12760743
[TBL] [Abstract][Full Text] [Related]
7. Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
Berardi F; Ferorelli S; Abate C; Pedone MP; Colabufo NA; Contino M; Perrone R
J Med Chem; 2005 Dec; 48(26):8237-44. PubMed ID: 16366605
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies.
Ferorelli S; Abate C; Colabufo NA; Niso M; Inglese C; Berardi F; Perrone R
J Med Chem; 2007 Sep; 50(19):4648-55. PubMed ID: 17713896
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiproliferative activity of 2,6-dibenzylamino-3,5-dicyanopyridines on human cancer cell lines.
Cocco MT; Congiu C; Lilliu V; Onnis V
Eur J Med Chem; 2005 Dec; 40(12):1365-72. PubMed ID: 16137795
[TBL] [Abstract][Full Text] [Related]
11. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
[TBL] [Abstract][Full Text] [Related]
12. 4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity.
Berardi F; Ferorelli S; Abate C; Colabufo NA; Contino M; Perrone R; Tortorella V
J Med Chem; 2004 Apr; 47(9):2308-17. PubMed ID: 15084129
[TBL] [Abstract][Full Text] [Related]
13. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635.
Lang L; Jagoda E; Ma Y; Sassaman MB; Eckelman WC
Bioorg Med Chem; 2006 Jun; 14(11):3737-48. PubMed ID: 16488611
[TBL] [Abstract][Full Text] [Related]
16. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties.
Kawai M; BaMaung NY; Fidanze SD; Erickson SA; Tedrow JS; Sanders WJ; Vasudevan A; Park C; Hutchins C; Comess KM; Kalvin D; Wang J; Zhang Q; Lou P; Tucker-Garcia L; Bouska J; Bell RL; Lesniewski R; Henkin J; Sheppard GS
Bioorg Med Chem Lett; 2006 Jul; 16(13):3574-7. PubMed ID: 16632353
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effects of SR31747A in animal cell lines are mediated by inhibition of cholesterol biosynthesis at the sterol isomerase step.
Labit-Le Bouteiller C; Jamme MF; David M; Silve S; Lanau C; Dhers C; Picard C; Rahier A; Taton M; Loison G; Caput D; Ferrara P; Lupker J
Eur J Biochem; 1998 Sep; 256(2):342-9. PubMed ID: 9760173
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists.
Lippa B; Morris J; Corbett M; Kwan TA; Noe MC; Snow SL; Gant TG; Mangiaracina M; Coffey HA; Foster B; Knauth EA; Wessel MD
Bioorg Med Chem Lett; 2006 Jul; 16(13):3444-8. PubMed ID: 16632359
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
Stewart AO; Cowart MD; Moreland RB; Latshaw SP; Matulenko MA; Bhatia PA; Wang X; Daanen JF; Nelson SL; Terranova MA; Namovic MT; Donnelly-Roberts DL; Miller LN; Nakane M; Sullivan JP; Brioni JD
J Med Chem; 2004 Apr; 47(9):2348-55. PubMed ID: 15084133
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
Su H; Nebbioso A; Carafa V; Chen Y; Yang B; Altucci L; You Q
Bioorg Med Chem; 2008 Sep; 16(17):7992-8002. PubMed ID: 18701301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
